C-reactive protein-triglyceride-glucose index was not clearly linked with self-reported stroke in humans (fully adjusted Model 3) (OR 1.17, 95% CI 0.93–1.48).
“In Model 3, continuous CTI was not significantly associated with self-reported stroke”
C-reactive protein-triglyceride-glucose index is linked with higher frailty progression in humans (compared with the low trajectory) (β = 0.263, 95% CI 0.074-0.451).
“linear mixed-effects modeling revealed accelerated deficit accumulation over time in this high-risk group (Chinese cohort: β = 0.263, 95% confidence interval 0.074-0.451”
C-reactive protein-triglyceride-glucose index was not clearly linked with asthma prevalence in humans (Fully adjusted model) (OR 1.07, 95% CI 0.99–1.16).
“The fully adjusted model revealed no significant association between CTI and asthma prevalence”
C-reactive protein-triglyceride-glucose index was not clearly linked with cardiovascular disease in humans (UK Biobank cohort, full adjustment) (OR = 1.08, 95% CI: 0.95-1.22).
“In the UK Biobank cohort, the CTI-CVD association attenuated progressively and became non-significant after full adjustment (OR = 1.08, 95% CI: 0.95-1.22, p = 0.261; AUC = 0.649).”
C-reactive protein-triglyceride-glucose index is linked with cardio-renal-metabolic multimorbidity in humans (sustained or progressive obesity trajectories) (approximately 42-54% of the associations).
“CTI mediated approximately 42-54% of the associations between sustained or progressive obesity trajectories and CRMM comorbidity outcomes.”
Humanssustained or progressive obesity trajectories
C-reactive protein-triglyceride-glucose index is associated with mortality in humans (cardiometabolic multimorbidity) (Per 1-SD increase: HR 1.17, 95% CI 1.07–1.29; highest versus lowest quartile: HR 1.75, 95% CI 1.30–2.37).
“Per 1-SD increase in CTI corresponded to a 17% higher mortality risk (HR=1.17, 95% CI 1.07–1.29)”
C-reactive protein-triglyceride-glucose index is associated with mortality in humans (Patients with chronic kidney disease and coronary artery disease; adjusted analysis) (HR 1.43, 95% CI 1.24–1.65).
“Adjusted models showed elevated composite indices linked to higher mortality (e.g., CTI HR 1.43 [95% CI 1.24–1.65] for all-cause; HR 1.32 [1.06–1.64] for CVD).”
HumansPatients with chronic kidney disease and coronary artery disease; adjusted analysisMedian follow-up of 63 monthsn = 1,353
C-reactive protein-triglyceride-glucose index is associated with mortality in humans (Postmenopausal women in NHANES with CTI below 5.43; per-unit CTI increase) (HR 0.99 per unit below CTI 5.43, 95% CI 0.89-1.10; P = 0.87).
“below, HR = 0.99 (95% CI 0.89-1.10; P = 0.87).”
HumansPostmenopausal women in NHANES with CTI below 5.43; per-unit CTI increaseMedian 11.9 yearsfemales
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·
C-reactive protein-triglyceride-glucose index predicts mortality in humans (Postmenopausal women; fully adjusted association per 1-unit CTI increase) (HR 1.28 per 1-unit increase, 95% CI 1.20-1.35).
“Each 1-unit CTI increase carried a 28% higher mortality hazard after full adjustment (hazard ratio [HR] 1.28; 95% confidence interval [CI] 1.20-1.35; P < 0.001).”
HumansPostmenopausal women; fully adjusted association per 1-unit CTI increasefemales
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·
C-reactive protein-triglyceride-glucose index is associated with mortality in humans (Adults with asthma; fully adjusted model) (HR 1.43, 95% CI 1.12–1.81).
“but showed a strong association with all-cause mortality (hazard ratio [HR], 1.43; 95% CI, 1.12-1.81; P = 0.004).”
HumansAdults with asthma; fully adjusted modeln = 1,832
C-reactive protein-triglyceride-glucose index is linked with a higher risk of mortality in humans (high vs low CTI group) (HR: 1.25, 95% CI 1.20–1.29).
“the high-CTI group exhibited an increased risks of T2D (HR: 3.60, 95% CI 3.39–3.83), stroke (HR: 1.11, 95% CI 1.03–1.19), CHD (HR: 1.52, 95% CI 1.46–1.58), first cardiometabolic disease (FCMD, HR: 1.86, 95% CI 1.81–1.92), CMM (HR: 2.50, 95% CI 2.23–2.80), and death (HR: 1.25, 95% CI 1.20–1.29).”
C-reactive protein-triglyceride-glucose index is associated with cardiovascular mortality in humans (Patients with chronic kidney disease and coronary artery disease; adjusted analysis) (HR 1.32, 95% CI 1.06–1.64).
“Adjusted models showed elevated composite indices linked to higher mortality (e.g., CTI HR 1.43 [95% CI 1.24–1.65] for all-cause; HR 1.32 [1.06–1.64] for CVD).”
HumansPatients with chronic kidney disease and coronary artery disease; adjusted analysisMedian follow-up of 63 monthsn = 1,353
C-reactive protein-triglyceride-glucose index predicts cardiovascular mortality in humans (per SD increase) (40% higher risk (95% CI: 1.20-1.62)).
“Each SD increase in CTI was associated with a 35% higher risk of all-cause mortality (95% CI: 1.24-1.48) and a 40% higher risk of cardiovascular mortality (95% CI: 1.20-1.62).”
Humansper SD increase152 months median follow-upn = 8,314
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular mortality in individuals with MASLD (HR 1.57, 95% CI 1.24-1.99).
“Each unit increase in CTI in NHANES was linked to a 57% increased risk of cardiovascular death (HR 1.57, 95% CI 1.24-1.99)”
C-reactive protein-triglyceride-glucose index is associated with cardiovascular mortality in humans (metabolic syndrome, quartile 4 vs quartile 1) (HR 1.60, 95% CI 1.13-2.25).
“However, Quartile 4 had significantly higher CV mortality (HR = 1.60; 95% CI: 1.13-2.25; P = .007).”
Humansmetabolic syndrome, quartile 4 vs quartile 1n = 10,421
C-reactive protein-triglyceride-glucose index predicts cardiovascular mortality in humans (metabolic syndrome) (HR 1.32, 95% CI 1.07-1.62).
“In a fully adjusted survey-weighted model, each 1-unit increase in CTI was associated with a 32% higher risk of CV mortality (hazard ratio [HR] = 1.32; 95% CI: 1.07-1.62; P = .010).”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular mortality in humans (highest tertile vs middle tertile) (HR 1.43, 95% CI: 1.16-1.76).
“Tertile comparisons showed that the highest group/tertile group had significantly increased risks for all-cause (adjusted HR 1.34, 95% CI: 1.19-1.51) and cardiovascular mortality (HR 1.43, 95% CI: 1.16-1.76)”
Humanshighest tertile vs middle tertilefemalesn = 5,582
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular mortality in humans (patients with diabetic foot) (HR = 1.50, 95% CI:1.06-2.11).
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular mortality in humans (AUC 0.8208).
“higher CTI levels were significantly associated with increased risks of all-cause and cardiovascular mortality across all three cohorts after full adjustment.”
Clinical research in cardiology : official journal of the German Cardiac Society·
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular mortality in humans (metabolic syndrome, quartile 4 vs quartile 1) (HR 1.72, 95% CI: 1.30–2.28).
“patients in quartile 4 had significantly higher CV mortality, with a hazard ratio of 1.72 (95% CI: 1.30–2.28, p<0.001)”
Humansmetabolic syndrome, quartile 4 vs quartile 1
C-reactive protein-triglyceride-glucose index is associated with cardiometabolic multimorbidity in humans (Chinese adults; fully adjusted model) (OR 1.57 per 1-SD increase, 95% CI 1.49–1.65).
“After standardization to a per-1-SD increase, CTI showed the strongest association (OR = 1.57, 95% CI: 1.49-1.65), followed by LAP (OR = 1.49) and AIP (OR = 1.44).”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiometabolic multimorbidity in humans (highest quartile vs lowest quartile) (HR 2.57, 95% CI 2.00–3.30).
“participants in the highest quartile of baseline CTI had a 2.57-fold higher risk of CMM compared with those in the lowest quartile (HR 2.57, 95% CI 2.00–3.30).”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiometabolic multimorbidity in humans (Q4 vs Q1) (HR 2.55 (95% CI 1.82-3.57)).
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiometabolic multimorbidity in humans (MASLD without CMDs at baseline) (HR 1.50 (95% CI 1.45-1.54)).
“and 1.50 (1.45-1.54) for CTI (all P < 0.001).”
HumansMASLD without CMDs at baseline16 yearsn = 109,181
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiometabolic multimorbidity in humans (HR 1.41, 95% CI 1.17–1.69).
“a 1‐standard deviation increase in the CTI was associated with a 41% higher CMM risk (hazard ratio [HR]: 1.41, 95% confidence interval [CI]: 1.17–1.69).”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiometabolic multimorbidity in humans (persistent high-risk change cluster (Cluster 2)) (HR = 2.37, 95% CI: 1.73–3.24).
“Both the moderate growth change cluster (Cluster 1) and the persistent high-risk change cluster (Cluster 2) were associated with significantly elevated CMM risks (HR = 1.89, 95% CI: 1.47–2.44; HR = 2.37, 95% CI: 1.73–3.24, respectively).”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiometabolic multimorbidity in humans (high vs low CTI group) (HR: 2.50, 95% CI 2.23–2.80).
“the high-CTI group exhibited an increased risks of T2D (HR: 3.60, 95% CI 3.39–3.83), stroke (HR: 1.11, 95% CI 1.03–1.19), CHD (HR: 1.52, 95% CI 1.46–1.58), first cardiometabolic disease (FCMD, HR: 1.86, 95% CI 1.81–1.92), CMM (HR: 2.50, 95% CI 2.23–2.80)”
C-reactive protein-triglyceride-glucose index predicts cardiometabolic multimorbidity in humans (adding CTI to traditional risk factors) (0.753 to 0.778).
“After adding CTI to a model containing traditional risk factors, the area under the receiver operating characteristic curve (AUC) for 4-year CMM prediction increased from 0.753 to 0.778.”
Humansadding CTI to traditional risk factors4-year
C-reactive protein-triglyceride-glucose index is linked with a higher risk of stroke in humans (mild cognitive impairment) (OR 1.34, 95% CI 1.04-1.72).
“each one-unit increase in CTI was associated with a 34% higher risk of stroke among MCI patients (Odds Ratio (OR): 1.34, 95% Confidence Interval (CI): 1.04-1.72, p < 0.05)”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of stroke in humans (highest tertile versus lowest in individuals at CKM stages 0-3) (HR 1.92, 95% CI 1.35-2.73).
“participants in the highest tertile of all CTI-related indices had significantly increased stroke risk, with hazard ratios (HRs) ranging from 1.92 (95%CI 1.35-2.73) for original CTI”
Humanshighest tertile versus lowest in individuals at CKM stages 0-3n = 3,348
C-reactive protein-triglyceride-glucose index is linked with a higher risk of stroke in humans (high CTI levels showing a slow increasing trend) (HR 1.75, 95% CI 1.25-2.48).
“and those with high CTI levels showing a slow increasing trend (HR = 1.75, 95% CI: 1.25-2.48, P < 0.001) had a significantly higher risk of stroke.”
Humanshigh CTI levels showing a slow increasing trendn = 4,364
C-reactive protein-triglyceride-glucose index is linked with a higher risk of stroke in humans (free of diabetes) (HR 1.76, 95% CI 1.34-2.30).
“Compared to the stable low group, a significant higher risk of stroke was only observed in the stable high group (hazard ratio [HR], 1.76; 95 % confidence interval [CI], 1.34-2.30)”
Humansfree of diabetesmedian follow-up of 3.50 yearsn = 5,973
C-reactive protein-triglyceride-glucose index is associated with cardiovascular disease in humans (fully adjusted overall population) (OR 1.194, 95% CI 1.112–1.282).
“each 1-unit increase in CTI was associated with prevalent CVD (OR 1.194, 95% CI 1.112–1.282; P <0.001)”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular disease in humans (fully adjusted overall population) (HR 1.096, 95% CI 1.024–1.174).
“each 1-unit increase in CTI was associated with prevalent CVD (OR 1.194, 95% CI 1.112–1.282; P <0.001) and incident CVD (HR 1.096, 95% CI 1.024–1.174; P =0.008)”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular disease in humans (rectal cancer survivors, discovery cohort) (OR = 1.18, 95% CI: 1.02-1.36).
“each one-SD increment in CTI was associated with an 18% higher risk of incident CVD (OR = 1.18, 95% CI: 1.02-1.36, p = 0.025)”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular disease in adults with arthritis (HR 1.251, 95% CI 1.083-1.446).
“baseline CTI was associated with incident CVD [hazard ratio (HR) = 1.251, 95% confidence interval (CI): 1.083-1.446, p = 0.002]”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular disease in humans (adjusted for demographic and clinical confounders).
“CTI and its modified indices all maintained robust, independent associations with incident CVD.”
Humansadjusted for demographic and clinical confounders
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular disease in humans (cancer survivors) (HR 1.65 [1.44-1.89]).
“high CTI-related indices were significantly and positively associated with incident CVD events (HR 1.65 [1.44–1.89])”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of cardiovascular disease in humans (prospective cohort) (HR up to 1.58).
“Higher CTI quartiles (Q3/Q4) were associated with a significantly elevated risk of CVD, particularly among males (hazard ratio [HR] up to 1.58) and middle-aged individuals (HR 1.57).”
Humansprospective cohortmedian follow-up period of 108.1 monthsn = 7,584
C-reactive protein-triglyceride-glucose index is associated with sarcopenia in humans (Fully adjusted analysis in Chinese adults) (Fully adjusted OR 0.732, 95% CI 0.615–0.869).
“Higher CTI levels were found to be inversely correlated with sarcopenia risk,”
HumansFully adjusted analysis in Chinese adults4 yearsboth; 53.9% femalesn = 5,741
C-reactive protein-triglyceride-glucose index predicts sarcopenia in humans (AUC: 0.730 (CHARLS), 0.722 (NHANES)).
“compared to CRP and the TyG index, CTI exhibited the best predictive capability for sarcopenia risk, with the highest AUC (CHARLS: 0.730, NHANES: 0.722)”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of sarcopenia in humans (OR: 1.52, 95 %CI: 1.15-1.99, P = 0.004).
“revealed the cross-sectional (OR: 1.52, 95 %CI: 1.15-1.99, P = 0.004) and longitudinal (HR: 1.35, 95 %CI: 1.10-1.65, P = 0.004) correlation between CTI and sarcopenia risk”
C-reactive protein-triglyceride-glucose index is associated with incident sarcopenia in humans (Chinese participants without sarcopenia at baseline) (Adjusted OR 0.89 per unit increase, 95% CI 0.79–0.98; highest versus lowest quartile OR 0.71, 95% CI 0.55–0.92).
“A higher baseline C-reactive protein–triglyceride–glucose index was associated with lower odds of incident sarcopenia”
HumansChinese participants without sarcopenia at baseline4 years
C-reactive protein-triglyceride-glucose index predicts incident sarcopenia in humans (Prediction analysis in Chinese adults; model composition not specified) (ROC AUC 0.831).
“The area under the ROC curve for prediction was 0.831.”
HumansPrediction analysis in Chinese adults; model composition not specified4 yearsboth; 53.9% femalesn = 5,741
C-reactive protein-triglyceride-glucose index is associated with chronic kidney disease in humans (adjusted for confounding variables) (OR 1.32, 95% CI 1.25–1.38).
“Logistic regression analysis revealed a positive association between CTI and CKD, even after adjusting for the confounding variables”
Humansadjusted for confounding variablesn = 12,396
C-reactive protein-triglyceride-glucose index is linked with a higher risk of chronic kidney disease in humans (OR = 1.26, 95% CI: 1.08, 1.47; P = .003).
“there was a positive association of CTI with the incidence of new-onset CKD (OR = 1.26, 95% CI: 1.08, 1.47; P = .003)”
C-reactive protein-triglyceride-glucose index is associated with incident stroke in humans (Highest versus lowest quartile; fully adjusted model) (Q4 versus Q1: OR 2.054, 95% CI 1.546–2.729).
“participants in the highest quartile of CTI (Q4) had a significantly higher risk compared to those in the lowest quartile (Q1)”
HumansHighest versus lowest quartile; fully adjusted model7 yearsn = 7,365
C-reactive protein-triglyceride-glucose index is associated with incident stroke in humans (High CTI; fully adjusted model; participants without baseline stroke) (HR 1.62, 95% CI 1.35–1.95).
“high CTI and high FI were independently associated with increased stroke risk”
C-reactive protein-triglyceride-glucose index is linked with a higher risk of frailty in humans (compared with the low trajectory) (HR 1.24, 95% CI 1.03-1.49).
“the high trajectory was independently associated with augmented incident frailty risk (Chinese cohort: hazard ratio 1.24, 95% confidence interval 1.03-1.49”
In 5,304 Chinese adults, one score was linked to new cardiovascular disease with a hazard ratio of 1.213 per standard-deviation increase.In 5,304 Chinese adults, one score was linked to new cardiovascular disease with a hazard ratio of 1.213 per standard-deviation increase.
Relative rates of developing multiple conditions were 3.40 in China and 2.62 in England for the highest-scoring quarter versus the lowest.Relative rates of developing multiple conditions were 3.40 in China and 2.62 in England for the highest-scoring quarter versus the lowest.
Who was studied7,108 adults in China and England, against adults in the lowest CTI-FI quartile
What changedRisk of multiple cardiometabolic conditions was higher with highest versus lowest combined scores: hazard ratios 3.40 (China) and 2.62 (England)
The catchSelf-reported heart disease and stroke diagnoses could misclassify who developed multiple conditions